Clinical trials of fatty acid treatment in ADHD, dyslexia, dyspraxia and the autistic spectrum

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 70, Issue 4, 2004, Pages 383-390

  Richardson, A J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ARACHIDONIC ACID; DEXAMPHETAMINE; DOCOSAHEXAENOIC ACID; FATTY ACID; FISH OIL; GAMMA LINOLENIC ACID; LINOLENIC ACID; OLIVE OIL; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PLACEBO; PRIMROSE OIL; THYME OIL;

ATTENTION DEFICIT DISORDER; AUTISM; CHILDHOOD DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; DIET SUPPLEMENTATION; DYSLEXIA; DYSPRAXIA; FAT INTAKE; HUMAN; METHODOLOGY; NUTRITIONAL DEFICIENCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 1842453654     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2003.12.020     Document Type: Conference Paper

References (41)

1. A.J. Richardson, M.A. Ross, Fatty acid metabolism in neurodevelopmental disorder: a new perspective on associations between attention-deficit/ hyperactivity disorder, dyslexia, dyspraxia and the autistic spectrum, Prostaglandius Leukot Essent Fatty Acids 63 (1-2) (2000) 1-9.
2. L.J. Stevens, et al., Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder, Am. J. Clin. Nutr. 62 (4) (1995) 761-768.
3. L.J. Stevens, et al., Omega-3 fatty acids in boys with behavior, learning, and health problems, Physiol. Behav. 59 (4-5) (1996) 915-920.
4. K.E. Taylor, et al., Dyslexia in adults is associated with clinical signs of fatty acid deficiency, Prostaglandius Leukot Essent Fatty Acids 63 (1-2) (2000) 75-78.
5. J.G. Bell, et al., Apparent fatty acid deficiency in autistic spectrum disorders, Prostaglandius Leukot Essent Fatty Acids, 2004, in press.
6. E.A. Mitchell, et al., Clinical characteristics and serum essential fatty acid levels in hyperactive children, Clin. Pediatr. Phila. 26 (8) (1987) 406-411.
7. S. Vancassel, et al., Plasma fatty acid levels in autistic children, Prostaglandius Leukot Essent Fatty Acids 65 (1) (2001) 1-7.
8. A.J. Richardson, et al., Abnormal cerebral phospholipid metabolism in dyslexia indicated by phosphorus-31 magnetic resonance spectroscopy, NMR Biomed. 10 (7) (1997) 309-314.
9. L.E. MacDonell, et al., Increased levels of cytosolic phospholipase A2 in dyslexics, Prostaglandius Leukot Essent Fatty Acids 63 (1-2) (2000) 37-39.
10. I. Colquhoun, S. Bunday, Alack of essential fatty acids as a possible cause of hyperactivity in children, Med. Hypotheses 7 (5) (1981) 613-619.
11. B.J. Stordy, Benefit of docosahexaenoic acid supplements to dark adaptation in dyslexics, Lancet 346 (8971) (1995) 385.
12. B.J. Stordy, Dark adaptation, motor skills, docosahexaenoic acid, and dyslexia, Am. J. Clin. Nutr. 71 (1 Suppl) (2000) 323S-326S.
13. J.G. Bell, et al., Red blood cell fatty acid compositions in a patient with autistic spectrum disorder: a characteristic abnormality in neurodevelopmental disorders? Prostaglandius Leukot Essent Fatty Acids 63 (1-2) (2000) 21-25.
14. M. Slade, S. Priebe, Are randomised controlled trials the only gold that glitters? Br. J. Psychiatry 179 (2001) 286-287.
15. M.G. Aman, E.A. Mitchell, S.H. Turbott, The effects of essential fatty acid supplementation by Efamol in hyperactive children, J. Abnorm. Child Psychol. 15 (1) (1987) 75-90.
16. L.E. Arnold, et al., Gamma-linolenic acid for attention-deficit hyperactivity disorder: placebo-controlled comparison to d-amphetamine, Biol. Psychiatry 25 (2) (1989) 222-228.
17. J.M. Bourre, et al., Brain cell and tissue recovery in rats made deficient in n-3 fatty acids by alteration of dietary fat, J. Nutr. 119 (1) (1989) 15-22.
18. L.E. Arnold, S.M. Pinkham, N. Votolato, Does zinc moderate essential fatty acid and amphetamine treatment of attention-deficit/hyperactivity disorder? J. Child Adolesc. Psychopharmacol. 10(2) (2000) 111-117.
19. A.P. Simopoulos, The importance of the ratio of omega-6/omega-3 essential fatty acids, Biomed. Pharmacother. 56 (8) (2002) 365-379.
20. J.R. Burgess, Attention deficit hyperactivity disorder: observational and interventional studies, in: NIH Workshop on Omega-3 Essential Fatty Acids and Psychiatric Disorders. National Institutes of Health, Bethesda, 1998.
21. L. Stevens, et al., EFA supplementation in children with inattention, hyperactivity and other disruptive behaviours, Lipids 38 (10) (2003) 1007-1021.
22. R.G. Voigt, et al., A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/ hyperactivity disorder, J. Pediatr. 139 (2) (2001) 189-196.
23. M. Peet, et al., Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia, Schizophr. Res. 49 (3) (2001) 243-251.
24. L.B. Marangell, et al., A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression, Am. J. Psychiatry 160 (5) (2003) 996-998.
25. B. Kadesjo, C. Gillberg, The comorbidity of ADHD in the general population of Swedish school-age children, J. Child Psychol. Psychiatry 42 (4) (2001) 487-492.
26. B. Nemets, Z. Stahl, R.H. Belmaker, Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder, Am. J. Psychiatry 159 (3) (2002) 477-479.
27. M. Peet, D.F. Horrobin, Adose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs, Arch. Gen. Psychiatry 59 (10) (2002) 913-919.
28. A.L. Stoll, et al., Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial, Arch. Gen. Psychiatry 56 (5) (1999) 407-412.
29. S. Hirayama, T. Hamazaki, K. Terasawa, The Effect of Foods Containing DHA on Symptoms of Attention-deficit Hyperactivity Disorder: A Randomised Controlled Trial, ISSFAL Meeting, Montreal, 2002.
30. A.J. Richardson, B.K. Puri, A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties, Prog. Neuropsychopharmacol. Biol. Psychiatry 26 (2) (2002) 233-239.
31. C.K. Conners, Conners' Parent Rating Scales - Revised, Multi-Health Systems Inc., New York, 1997.
32. A.J. Richardson, Clinical trials of fatty acid supplementation in Dyslexia and Dyspraxia, in: M. Peet, G.I., D.F. Horrobin (Eds.), Phospholipid Spectrum Disorders in Psychiatry and Neurology, Marius Press, Carnforth, 2003, pp. 491-500.
33. M. Peet, I. Glen, D.F. Horrobin (Eds.), Phospholipid Spectrum Disorders in Psychiatry and Neurology, 2nd Edition, Marius Press, Carnforth, 2003.
34. M. Peet, D.F. Horrobin, E-E-Multicentre-Study-Group, A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms, J. Psychiatry Res. 36 (1) (2002) 7-18.
35. K.P. Su, et al., Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial, Eur. Neuropsychopharmacol. 13 (4) (2003) 267-271.
36. B.K. Puri, A.J. Richardson, The effects of olive oil on omega3 fatty acids and mood disorders, Arch. Gen. Psychiatry 57 (7) (2000) 715.
37. T. Sugiura, et al., Enzymatic synthesis of oleamide (cis-9, 10-octadecenoamide), an endogenous sleep-inducing lipid, by rat brain microsomes, Biochem. Mol. Biol. Int. 40 (5) (1996) 931-938.
38. B.F. Cravatt, et al., Chemical characterization of a family of brain lipids that induce sleep, Science 268 (5216) (1995) 1506-1509.
39. D.L. Boger, S.J. Henriksen, B.F. Cravatt, Oleamide: an endogenous sleep-inducing lipid and prototypical member of a new class of biological signaling molecules, Curr. Pharm. Des. 4 (4) (1998) 303-314.
40. S. Huitron-Resendiz, et al., Effect of oleamide on sleep and its relationship to blood pressure, body temperature, and locomotor activity in rats, Exp. Neurol. 172 (1) (2001) 235-243.
41. I. Fedorova, et al., Behavioral evidence for the interaction of oleamide with multiple neurotransmitter systems, J. Pharmacol. Exp. Ther. 299 (1) (2001) 332-342.